We report a case of pure red cell aplasia (PRCA) following allogeneic peripheral blood stem cell transplantation (PBSCT) for aplastic anemia with major ABO mismatch that proved resistant to all standard treatment options including oral prednisolone, reduction in immunosuppressive treatment, erythropoietin (EPO) and Rituximab. Finally, high-dose dexamethasone for 4 days resolved the PRCA in our patient, 388 days after SCT and 40 days after the first dose of dexamethasone.
A 38-year-old male with severe aplastic anemia under- No manipulation of the graft was carried out and there were no hemolytic complications. Cyclosporine and short course methotrexate were used as GVHD prophylaxis. An absolute neutrophil count of 4500/mm 3 was achieved on day þ 14, whereas an unsupported platelet count of 420 000/mm 3 was achieved on day þ 13.
Following the transplant the patient continued to run a low hemoglobin (6.2-7.8 gm/dl) with a low reticulocyte count (0.1-0.3%) despite complete donor chimerism on VNTR analysis, and even after day þ 60 he continued to require blood transfusions every 2 weeks.
Bone marrow examination confirmed the diagnosis of PRCA with less than 5% erythroid precursors and the following therapies were tried without significant reduction in transfusion requirement or increase in reticulocyte count:
1. Oral prednisolone -40 mg daily for 6 weeks from day þ 127 to þ 174. 2. Rituximab À375 mg/m 2 on day þ 183. This lead to a fourfold reduction in IgM and IgG titer but with no reticulocyte response. 3. Erythropoietin -10 000 IU thrice weekly from day þ 285 to day þ 315, 16 doses for 4 weeks, which resulted in a decrease in anti-A titers at the end of therapy to 1:2 IgM and and 1:4 IgG. 4. Cyclosporine was reduced with the aim of facilitating graft-versus-recipient depletion of residual B lymphocytes. Dose reduction was started on day þ 240 and the drug was stopped on day þ 326. 5. Finally, he was treated with high-dose dexamethasone 40 mg intravenously for 4 days from day þ 348 to day þ 352. He had a significant response to this therapy, with an increase in hemoglobin from 7.3 gm/dl to 8.5 gm/dl (day þ 353) and an increase in reticulocyte count from 0.2 to 1.2%. By day þ 374, the hemoglobin levels had increased to 11.3 gm/dl with a reticulocyte count of 2.4%. His blood group had converted to A Rh positive and the anti-A titers further reduced to 1:2 IgM and 1:2 IgG by day þ 388 (Figure 1 ). The hemoglobin steadily increased to 11.9gm% with a reticulocyte count of 1.8% on day þ 416 and remained stable until discharge on day þ 420. He continues to be asymptomatic with a normal hemoglobin level and reticulocyte count, 27 months after PBSCT. Chimerism analysis, using the tho1 marker on peripheral blood, showed complete donor chimerism.
Pure red cell aplasia occurs in around 20% of patients receiving transplants with major ABO incompatibility and the post transplant increase of isoagglutinins is a significant predictor of PRCA. Presence and persistence of isoagglutinins may delay red cell engraftment and be the cause of PRCA. 1 The mechanism of prolonged PRCA after ABO-incompatible BMT is complement-mediated immune Bone
www.nature.com/bmt destruction of erythroid progenitors past the stage of BFU-E differentiation. 2 The persistence of isoagglutinins is due to antibody-producing plasma cells of recipient origin which are not destroyed by the conditioning regimen.
3 A graft-vsplasma cell effect is thought to be responsible for the rapidity of isoagglutinin disappearance after transplantation. 3 Immunological changes due to withdrawal of cyclosporin A, 4 or development of GVHD, are followed by rapid resolution of delayed rbc engraftment. Many treatment options have been reported in the literature including high-dose EPO, 5 plasma exchange, immunoadsorption, antithymocyte globulin, Rituximab, 6 DLI, lowdose steroids 7 and bolus methylprednisolone. Evaluation of the efficacy of any treatment is difficult because of the eventual spontaneous resolution of PRCA post-transplantation. 8 In this patient, low-dose oral prednisolone, singledose Rituximab, erythropoietin and induction of chronic GVHD by reduction of cyclosporine were all ineffective.
High-dose dexamethasone 9 is effective in refractory chronic ITP and this was therefore tried, with good response in this patient.
Therapy with dexamethasone is a low cost therapeutic option for the management of post-transplant PRCA in an ABO-mismatched transplant.
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